AIDS vaccine trial set to start
The US government is poised to start a new AIDS vaccine trial, prompting some to caution that it is too soon to initiate such studies after a linkurl:Merck vaccine;https://www.the-scientist.com/blog/display/53633/ not only failed to show effectiveness but also may have increased participants' HIV infection rate. Late last week, the NIH's linkurl:AIDS Vaccine Research Subcommittee;https://www3.niaid.nih.gov/research/topics/HIV/vaccines/advisory/avrs/ voted 23-3 in favor of beginning the PAVE 100 H
The Scientist ARCHIVES
Become a Member of
Add The Scientist as a preferred Google source to see more of our trusted coverage.
Meet the Author
From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.
View Full Profile
